GleamWall
中文EN

QNRX Quoin Pharmaceuticals Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671502

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-142.5%
ROA-95.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio7.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.66M$3.63M$3.43M$3.10M$2.28M$2.05M$2.37M$1.07M
SG&A expense$2.27M$1.85M$1.70M$1.42M$1.74M$1.74M$1.58M$1.33M
Net income-$4.87M-$5.37M-$5.00M-$4.35M-$3.95M-$3.70M-$3.81M-$2.31M
EPS (diluted)————————
Balance sheet
Cash & equivalents$10.10M$3.85M$3.12M$3.82M$1.83M$1.67M$3.82M$3.62M
Short-term investments$23.08M$6.95M$10.92M$14.93M———$10.43M
Current assets$34.40M$11.64M$15.33M$20.01M$6.02M$8.48M$12.50M$14.93M
Intangibles$308,334$333,334$358,334$383,334$408,334$433,334$458,334$483,334
Total assets$34.75M$11.97M$15.69M$20.39M$6.42M$8.91M$12.96M$15.71M
Current liabilities$4.78M$6.61M$5.35M$5.55M$5.76M$4.34M$4.86M$4.18M
Total liabilities$6.05M$8.04M$6.92M$7.27M$7.64M$6.36M$7.03M$6.50M
Shareholders' equity$28.70M$3.93M$8.77M$13.12M-$1.21M$2.55M$5.93M$9.20M
Shares outstanding168.15M70.29M68.64M52.44M20.59M20.59M20.59M8.95M
Cash flow statement
Operating cash flow-$5.77M-$3.14M-$4.87M-$5.04M-$2.23M-$3.69M-$2.59M-$2.24M
Investing cash flow-$16.09M$4.02M$4.12M-$11.27M$2.54M$1.68M$2.77M-$3.18M
Financing cash flow$28.11M-$151,947$55,982$18.29M-$150,000-$150,000$22,958$5.92M
Stock-based compensation$484,000$532,000$444,525$283,205$182,000$321,000$360,357$326,332

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.